{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:46:43Z","timestamp":1777985203178,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T00:00:00Z","timestamp":1473724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the effect of 25 or 50 mg mirabegron on cardiovascular end\u2010points and adverse drug reactions in real\u2010world Japanese patients with overactive bladder and cardiovascular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants had overactive bladder, a history of\/coexisting cardiovascular disease and a 12\u2010lead electrocardiogram carried out \u22647 days before initiating 4 weeks of mirabegron treatment. Patients with \u201cserious cardiovascular disease\u201d (class III or IV on the New York Heart Association functional classification and further confirmed by expert analysis) were excluded. Patient demographics, physical characteristics and cardiovascular history were recorded. After 4 weeks, patients underwent another electrocardiogram. Incidence of cardiovascular adverse drug reactions and change from baseline in electrocardiogram parameters (RR, PR, QRS intervals, Fridericia's corrected QT and heart rate) were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 316 patients registered, 236 met criteria and had baseline\/post\u2010dose electrocardiograms: 61.9% male; 60.2% aged \u226575 years; 93.6% with coexisting cardiovascular disease, notably, arrhythmia (67.8%) and angina pectoris (19.1%). Starting mirabegron daily doses were 25 mg (19.9%) or 50 mg (80.1%). The incidence of cardiovascular adverse drug reactions was 5.51%. After 4 weeks, the mean heart rate increased by 1.24 b.p.m. (statistically significant, but clinically acceptable as per previous trials). No significant changes were observed in PR, QRS or Fridericia's corrected QT. No significant correlations in the total population or age\u2010\/sex\u2010segregated subgroups were observed between baseline Fridericia's corrected QT and change at 4 weeks. No correlation for heart rate versus change from baseline heart rate with treatment was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mirabegron was well tolerated in real\u2010world Japanese patients with overactive bladder and coexisting cardiovascular disease. No unexpected cardiovascular safety concerns were observed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.13218","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T02:06:51Z","timestamp":1473818811000},"page":"1009-1015","source":"Crossref","is-referenced-by-count":19,"title":["Real\u2010world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post\u2010marketing study"],"prefix":"10.1111","volume":"23","author":[{"given":"Takao","family":"Katoh","sequence":"first","affiliation":[{"name":"Cardiovascular Center Mita Hospital International University of Health and Welfare Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Kuwamoto","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kato","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentarou","family":"Kuroishi","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09993.x"},{"key":"e_1_2_8_4_1","first-page":"6","article-title":"Maximizing the treatment of overactive bladder in the elderly","volume":"10","author":"Macdiarmid SA","year":"2008","journal-title":"Rev. Urol."},{"key":"e_1_2_8_5_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).Assessment report: Betmiga. European Medicines Agency 2012. [Cited 19 Jan 2016.] Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002388\/WC500137308.pdf"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05835.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11023.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2009.15.9.728"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.142562"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22505"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-13-45"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61994-3"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-008-0274-y"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01635-1"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0031-6997(24)01425-X","article-title":"Adrenergic and muscarinic receptors in the human heart","volume":"51","author":"Brodde OE","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.181"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12194"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.048"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10436.x"},{"key":"e_1_2_8_20_1","volume-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"The Criteria Committee of the New York Heart Association","year":"1994"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.09.007"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09073.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12649"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.10.017"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.02.077"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12148"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.13218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.13218","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.13218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T18:36:15Z","timestamp":1749580575000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.13218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/iju.13218"],"URL":"https:\/\/doi.org\/10.1111\/iju.13218","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,13]]}}}